![](https://static.biospace.com/dims4/default/e13a823/2147483647/strip/true/crop/360x180+0+0/resize/200x100!/quality/90/?url=https%3A%2F%2Fk1-prod-biospace.s3.us-east-2.amazonaws.com%2Fbrightspot%2Flegacy%2FBioSpace-Assets%2FD196E10F-9D7D-42C3-8C93-DEB892ACC0B6.png)
Aspen Neuroscience
NEWS
Recent funding saw support for a platform that selectively degrades DNA, software to help read mammograms and a company using corn genetics to develop cancer-targeting viruses.
Aspen Neuroscience closed on a Series B funding round of $147.5 million. The company is focused on developing personalized cell replacements for Parkinson’s disease.
BioSpace is proud to present its NextGen Bio “Class of 2021,” a list of up-and-coming life science startups in North America that recently launched.
IN THE PRESS